Amylyx welcomes former Alnylam exec to help expand Relyvrio; Amarin plugs in an interim chief
→ Masako Nakamura will lead Relyvrio’s march to key regions as Amylyx’s general manager and head of the Asia Pacific and Latin America international markets. Nakamura, the SVP, head of Asia at Alnylam from 2018-21, tackled a similar gig as GM, Asia with Aegerion Pharmaceuticals and had a 10-year career at Genzyme. Canada approved Amylyx’s ALS drug, known in that country as Albrioza, in June 2022, while the FDA gave it the go-ahead in September following an unconventional second adcomm.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
